Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Kidney Cancer Clinical Trials

A listing of Kidney Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (138) clinical trials

CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation

This is a Phase 1, multi-center, open-label, 2-part study with a Dose Escalation Segment and Dose and Disease Expansion Cohorts study of CBT-101, a c-MET inhibitor, to determine the recommended Phase 2 dose (RP2D) and dose limiting toxicities for CBT-101, and to obtain preliminary efficacy and target engagement data, in ...

Phase

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of investigational drugs to learn whether the drugs work in treating a specific disease. "Investigational" means that the intervention is being studied. Nivolumab and ipilimumab are antibodies (a type of human protein) ...

Phase

Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study of CK-301, a fully human monoclonal IgG1 antibody targeting PD-L1. The study will consist of 3 periods: Screening (up to 28 days), Treatment (28-day cycles), and Follow-up (up to 6 months). Following the dose escalation portion of the study, additional ...

Phase

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers

The trial will be conducted in 2 parts: dose escalation (Phase I ) and dose expansion (Phase 2) . During Phase 1, patients with advanced solid tumors are eligible if the tumor has progressed following or has not adequately responded to standard therapy, or if the patient is intolerant of, ...

Phase

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

OBJECTIVES: Primary - Estimate the response, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma (RCC) treated with bevacizumab and high-dose interleukin-2 (IL-2). Secondary - Compare the response and survival of patients with metastatic RCC treated with bevacizumab and high-dose IL-2 with the historical data of patients ...

Phase

Vaccine Therapy in Treating Patients With Newly Diagnosed Stage IV Kidney Cancer

OBJECTIVES: Primary - Determine the biological and clinical responses, in terms of measured T-cell responses, of two different induction vaccination regimens comprising autologous dendritic cells transfected with autologous tumor mRNA and human CD40 ligand in patients with newly diagnosed stage IV clear cell renal cell carcinoma. Secondary - Determine safety ...

Phase

Imaging Study in Patients With Cancer of the Head & Neck Lung Renal Cell Brain Lymphoma and Neuroendocrine Tumours

The proposed clinical trial will be a Phase I/II imaging, open label, single site study. In Phase I, one 18F-FAZA PET scan will be conducted in patients with known squamous cell carcinoma of the Head & Neck, SCLC, NSCLC, lymphoma, GGM, neuroendocrine tumours or renal cell carcinoma. In Phase II, ...

Phase

Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia Hemihypertrophy and Genitourinary Anomalies

If you choose to take part in this study, blood (about 10 teaspoons) will be drawn for genetic testing. The blood may be drawn more than 1 time, depending on how much blood is drawn at the first visit, and if you are available for more blood draws. If this ...

Phase N/A

CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide

OBJECTIVES: Primary - To determine the CYP3A5 genotype in young patients with cancer who have received ifosfamide. - To document renal function and nephrotoxicity on one occasion between 1 month and 5 years after completion of ifosfamide treatment. - To determine the relationship between CYP3A5 genotype and ifosfamide nephrotoxicity. Secondary ...

Phase N/A

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

OBJECTIVES: Primary - To determine the objective tumor response rate in patients with locally advanced or metastatic papillary renal cell carcinoma treated with sunitinib malate. Secondary - To evaluate the safety of this drug in these patients. - To determine time-to-event variables of overall survival, time to disease progression, time ...

Phase